Tolerance of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors in Patients With Self-Reported Statin Intolerance
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pharmacy Practice"
DOI: 10.1177/0897190018799218
Abstract: Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to lower atherogenic lipid markers in patients with statin intolerance; however, external validity of these findings is unclear in patients with self-reported statin intolerance.… read more here.
Keywords: statin intolerance; pcsk9 inhibitors; intolerance; reported statin ... See more keywords